Table 5:
Fixed Quarterly Visits and PRN A-VEGF Re-treatment on Outcomes in RCTs for n-AMD
| Study Group | Δ ETDRS BCVA Letters Mean | Proportion (%) Gaining ≥ 15 Letters | Δ CRT μm Mean | |||
|---|---|---|---|---|---|---|
| 0–3 months | 0–2 months | 0–3 months | 0–12 months | 0–3 months | 0–12 months | |
| Treatment naïve, 0.3 mg | 5.8 | 0.5 | 19.4 | 14.6 | –107.0 | –72.0 |
| Treatment naïve, 0.5 mg | 7.0 | 2.3 | 20.1 | 19.3 | –122.0 | –92.0 |
| Previously treated, 0.3 mg | 4.6 | 1.7 | 16.0 | 15.8 | –98.0 | –71.0 |
| Previously treated, 0.5 mg | 5.8 | 2.3 | 18.6 | 16.5 | –108.0 | –76.0 |
Source: Boyer et al. (50)
Abbreviations: BCVA; Best corrected visual acuity; CRT, Central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; n-AMD, neovascular age-related macular degeneration; PRN, pro re nata (as needed).